Could cause temporary or reversible harm; serious harm is unlikely.
Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.
| Distributed by / for | Teva Pharmaceuticals USA, Inc. |
| NDC | 0555-0096-96 |
| Full product label | CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96 |
| Recalling firm | Teva Pharmaceuticals USA, Inc. |
| Distribution | NC |
| Quantity | 3 boxes |
| Recall initiated | 2013-02-07 |
| Report date | 2013-04-10 |
| Recall completed | 2014-01-15 |
| Recall number | D-237-2013 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Sellersville PA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗